Prostate-specific membrane antigen expression is great lymph node metastases

Urology

52, 637-640

DOI: 10.1016/s0090-4295(98)00278-7

Citation Report

#	Article	IF	Citations
1	Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer, 1998, 83, 2259-2269.	2.0	162
2	Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer and Metastasis Reviews, 1999, 18, 483-490.	2.7	61
3	Report on Prostate Cancer Tumor Marker Workshop 1999. Cancer, 2000, 88, 955-963.	2.0	11
4	Serum levels of PSMA. , 2000, 42, 318-319.		19
5	Detection of extraprostatic prostate cells utilizing reverse transcription-polymerase chain reaction. , 2000, 18, 17-28.		29
6	Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate, 2000, 45, 350-354.	1.2	112
7	Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy. Cancer, 2000, 89, 2577-2586.	2.0	37
8	Capromab Pendetide Imaging of Prostate Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2000, 15, 131-140.	0.7	55
9	Isolation and Characterization of Monoclonal Antibodies Specific for Protein Conformational Epitopes Present in Prostate-Specific Membrane Antigen (PSMA). Hybridoma, 2000, 19, 249-257.	0.9	27
10	Prostate cancer: therapeutic patent review. Expert Opinion on Therapeutic Patents, 2000, 10, 1833-1842.	2.4	1
11	Generation of a Baculovirus Recombinant Prostate-Specific Membrane Antigen and Its Use in the Development of a Novel Protein Biochip Quantitative Immunoassay. Protein Expression and Purification, 2000, 19, 12-21.	0.6	49
12	Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. Urology, 2000, 56, 988-993.	0.5	106
13	Prostate-specific membrane antigen: present and future applications. Urology, 2000, 55, 622-629.	0.5	36
14	Naked DNA and Adenoviral Immunizations for Immunotherapy of Prostate Cancer: A Phase I/II Clinical Trial. European Urology, 2000, 38, 208-217.	0.9	159
15	Brain Metastasis: An Unusual Complication From Prostatic Adenocarcinoma. Mayo Clinic Proceedings, 2000, 75, 79-82.	1.4	42
16	PSMA specific antibodies and their diagnostic and therapeutic use. Expert Opinion on Investigational Drugs, 2001, 10, 511-519.	1.9	49
17	New concepts in the pathology of prostatic epithelial carcinogenesis. Urology, 2001, 57, 103-114.	0.5	35
18	Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis, 2002, 23, 967-976.	1.3	121

#	Article	IF	Citations
19	Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Human Pathology, 2002, 33, 1136-1140.	1.1	102
20	Induction of Antibodies against Prostate-Specific Membrane Antigen (PSMA) by Vaccination with a PSMA DNA Vector. European Urology, 2002, 42, 67-73.	0.9	6
21	Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA. International Journal of Cancer, 2002, 102, 244-249.	2.3	13
22	Recombinant glutamate carboxypeptidase II (prostate specific membrane antigen--PSMA)--cellular localization and bioactivity analyses. The Protein Journal, 2003, 22, 317-326.	1.1	6
23	Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Seminars in Oncology, 2003, 30, 667-676.	0.8	146
24	Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. International Journal of Cancer, 2003, 107, 323-329.	2.3	85
25	Molecular imaging in prostate cancer. Journal of Cellular Biochemistry, 2003, 90, 473-483.	1.2	30
26	Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell line. Prostate, 2003, 55, 9-19.	1.2	23
27	Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model. Prostate, 2003, 55, 308-316.	1.2	21
28	Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen. Prostate, 2003, 57, 140-151.	1.2	47
29	Clinical Use of Monoclonal Antibody HuJ591 Therapy: Targeting Prostate Specific Membrane Antigen. Journal of Urology, 2003, 170, S84-8; discussion S88-9.	0.2	122
30	Targeting Metastatic Prostate Cancer With Radiolabeled Monoclonal Antibody J591 to the Extracellular Domain of Prostate Specific Membrane Antigen. Journal of Urology, 2003, 170, 1717-1721.	0.2	238
31	NFATc1 with AP-3 Site Binding Specificity Mediates Gene Expression of Prostate-specific-membrane-antigen. Journal of Molecular Biology, 2003, 330, 749-760.	2.0	32
32	Targeted Î±-therapy for control of micrometastatic prostate cancer. Expert Review of Anticancer Therapy, 2004, 4, 459-468.	1.1	25
33	Targeting Gene Therapy for Prostate Cancer. Current Pharmaceutical Design, 2004, 10, 531-555.	0.9	16
34	Detection of Prostate Cancer and Predicting Progression. Clinical Cancer Research, 2004, 10, 3943-3953.	3.2	151
35	Gene-based therapy in prostate cancer. Lancet Oncology, The, 2004, 5, 469-479.	5.1	23
36	Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate-specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging. BJU International, 2005, 95, 1232-1236.	1.3	30

#	Article	IF	Citations
37	Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. International Journal of Cancer, 2005, 116, 415-421.	2.3	51
38	Antibody-based therapeutics: Focus on prostate cancer. Cancer and Metastasis Reviews, 2005, 24, 521-537.	2.7	44
39	GENE THERAPY FOR PROSTATE CANCER. , 2005, , 75-105.		0
40	Development of a Radiolabeled Monoclonal Antibody to Prostate-Specific Membrane Antigen. , 2005, , 617-625.		0
41	Pilot Trial of Unlabeled and Indium-111â€“Labeled Antiâ€“Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer. Clinical Cancer Research, 2005, 11, 7454-7461.	3.2	120
42	Is prostate-specific membrane antigen a multifunctional protein?. American Journal of Physiology - Cell Physiology, 2005, 288, C975-C981.	2.1	184
43	Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer. Journal of Clinical Oncology, 2005, 23, 4591-4601.	0.8	468
44	N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy. Molecular Cancer Therapeutics, 2005, 4, 704-714.	1.9	30
45	Targeted therapies for prostate cancer. Expert Opinion on Therapeutic Targets, 2005, 9, 283-298.	1.5	12
46	Immunotherapy for Prostate Cancer. American Journal of Cancer, 2006, 5, 331-339.	0.4	0
47	Future Innovations in Treating Advanced Prostate Cancer. Urologic Clinics of North America, 2006, 33, 247-272.	0.8	3
48	Immunotherapy for Prostate Cancer: What's the Future?. Hematology/Oncology Clinics of North America, 2006, 20, 965-983.	0.9	6
49	85 Gene-based therapy in prostate cancer. Radiotherapy and Oncology, 2006, 78, S30.	0.3	0
50	Association of prostate-specific membrane antigen with caveolin-1 and its caveolae-dependent internalization in microvascular endothelial cells: Implications for targeting to tumor vasculature. Microvascular Research, 2006, 72, 54-61.	1.1	27
51	Expression of Prostate-Specific Membrane Antigen in Normal and Malignant Human Tissues. World Journal of Surgery, 2006, 30, 628-636.	0.8	279
52	Technology Insight: monoclonal antibody imaging of prostate cancer. Nature Reviews Urology, 2006, 3, 216-225.	1.4	119
53	Innovative Strategies for Image-Guided Proton Treatment of Prostate Cancer. Technology in Cancer Research and Treatment, 2006, 5, 91-100.	0.8	4
54	Clinical Trials of Cancer Therapies Targeting Prostate-Specific Membrane Antigen. Reviews on Recent Clinical Trials, 2007, 2, 182-190.	0.4	67

#	Article	IF	Citations
55	Selective High-Affinity Ligand Antibody Mimics for Cancer Diagnosis and Therapy: Initial Application to Lymphoma/Leukemia. Clinical Cancer Research, 2007, 13, 5621s-5628s.	3.2	28
56	A Novel Alphavirus Vaccine Encoding Prostate-Specific Membrane Antigen Elicits Potent Cellular and Humoral Immune Responses. Clinical Cancer Research, 2007, 13, 3999-4008.	3.2	59
57	Amphipathic Peptide-Based Fusion Peptides and Immunoconjugates for the Targeted Ablation of Prostate Cancer Cells. Cancer Research, 2007, 67, 6368-6375.	0.4	61
58	Immunohistochemical Differentiation of High-grade Prostate Carcinoma From Urothelial Carcinoma. American Journal of Surgical Pathology, 2007, 31, 1246-1255.	2.1	192
59	Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Human Pathology, 2007, 38, 696-701.	1.1	388
60	Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix. International Journal of Oncology, 0, , .	1.4	5
61	Proteomic Mapping of Endothelium and Vascular Targeting in Vivo. , 2007, , 881-897.		5
62	Identification of a novel prostate cancer-associated tumor antigen. Prostate, 2007, 67, 274-287.	1.2	16
63	High expression of PSM-E correlated with tumor grade in prostate cancer: A new alternatively spliced variant of prostate-specific membrane antigen. Prostate, 2007, 67, 1791-1800.	1.2	22
64	Molecular staging of prostate cancer in the year 2007. World Journal of Urology, 2007, 25, 19-30.	1.2	41
65	Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis. Clinical Biochemistry, 2008, 41, 1191-1198.	0.8	34
66	Selective Gene Therapy for Prostate Cancer Cells Using Liposomes Conjugated with IgM Type Monoclonal Antibody against Prostate-Specific Membrane Antigen. Human Cell, 2005, 18, 17-23.	1.2	11
67	Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2008, 49, 2031-2041.	2.8	118
68	Prostate-Specific Membrane Antigen Expression Is a Potential Prognostic Marker in Endometrial Adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 571-577.	1.1	21
69	Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using ¹¹¹In-J591: Lesion Detectability and Dosimetric Projections for ⁹⁰Y Radioimmunotherapy. Journal of Nuclear Medicine, 2008, 49, 1066-1074.	2.8	76
70	Phase I Trial of the Prostate-Specific Membrane Antigenâ€"Directed Immunoconjugate MLN2704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2008, 26, 2147-2154.	0.8	135
71	Detection of Circulating Tumor Cells in Prostate Cancer Patients: Methodological Pitfalls and Clinical Relevance. Molecular Medicine, 2009, 15, 101-114.	1.9	96
72	Preclinical Evaluation of a Monoclonal Antibody (3C6) Specific for Prostate-Specific Membrane Antigen. Current Radiopharmaceuticals, 2009, 2, 9-17.	0.3	27

#	Article	IF	Citations
73	PET Imaging of Prostate Cancer Xenografts with a Highly Specific Antibody against the Prostate-Specific Membrane Antigen. Journal of Nuclear Medicine, 2009, 50, 606-611.	2.8	92
74	Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer. Cancer Research, 2009, 69, 6932-6940.	0.4	279
75	Expression of the gastrinâ€releasing peptide receptor, the prostate stem cell antigen and the prostateâ€specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate, 2009, 69, 1101-1108.	1.2	139
76	Dendritic cells transduced with a PSMA-encoding adenovirus and cocultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against prostate cancer cells. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 26-32.	0.8	14
77	Targeting the prostate-specific membrane antigen for prostate cancer therapy. Immunotherapy, 2009, 1, 471-481.	1.0	17
78	Use of ¹¹¹ In-Capromab Pendetide Immunoscintigraphy to Image Localized Prostate Cancer Foci Within the Prostate Gland. Journal of Urology, 2009, 182, 938-948.	0.2	11
79	Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted ^{99m}Tc-Radioimaging Agents. Molecular Pharmaceutics, 2009, 6, 790-800.	2.3	147
80	Prostate Cancer: Role of SPECT and PET in Imaging Bone Metastases. Seminars in Nuclear Medicine, 2009, 39, 396-407.	2.5	106
81	Gene Expression Signature and the Prediction of Lymph Node Metastasis in Colorectal Cancer by DNA Microarray. Diseases of the Colon and Rectum, 2009, 52, 1941-1948.	0.7	27
83	NKX3.1 as a Marker of Prostatic Origin in Metastatic Tumors. American Journal of Surgical Pathology, 2010, 34, 1097-1105.	2.1	243
84	Positron emission tomography imaging of prostate cancer. Amino Acids, 2010, 39, 11-27.	1.2	60
85	Antiâ€“prostateâ€specific membrane antigenâ€based radioimmunotherapy for prostate cancer. Cancer, 2010, 116, 1075-1083.	2.0	120
86	Polylactide nanoparticles containing stably incorporated cyanine dyes for in vitro and in vivo imaging applications. Microscopy Research and Technique, 2010, 73, 901-909.	1.2	42
87	Angiogenesis as a strategic target for prostate cancer therapy. Medicinal Research Reviews, 2010, 30, 23-66.	5.0	42
88	Promising tumorâ€associated antigens for future prostate cancer therapy. Medicinal Research Reviews, 2010, 30, 67-101.	5.0	25
89	Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate, 2010, 70, 562-569.	1.2	70
90	Differential Gene Expression in Benign Prostate Epithelium of Men with and without Prostate Cancer: Evidence for a Prostate Cancer Field Effect. Clinical Cancer Research, 2010, 16, 5414-5423.	3.2	42
91	Angiogenesis inhibitors in the treatment of prostate cancer. Expert Opinion on Pharmacotherapy, 2010, 11, 233-247.	0.9	34

#	Article	IF	Citations
92	In Vivo Tumor Grading of Prostate Cancer Using Quantitative ¹¹¹In-Capromab Pendetide SPECT/CT. Journal of Nuclear Medicine, 2010, 51, 31-36.	2.8	29
93	IRX-2 increases the T cell-specific immune response to protein/peptide vaccines. Vaccine, 2010, 28, 7054-7062.	1.7	12
94	In VitroandIn VivoResponses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen. Molecular Cancer Therapeutics, 2011, 10, 1728-1739.	1.9	102
96	Prostate Gland. , 2011, , 299-319.		2
97	Molecular Imaging and Metastasis. , 0, , 516-537.		0
98	Diagnostic Performance of In-111 Capromab Pendetide SPECT/CT in Localized and Metastatic Prostate Cancer. Clinical Nuclear Medicine, 2011, 36, 872-878.	0.7	22
99	Lentivirus-mediated RNAi knockdown of prostate-specific membrane antigen suppresses growth, reduces migration ability and the invasiveness of prostate cancer cells. Medical Oncology, 2011, 28, 878-887.	1.2	6
100	High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer. Prostate, 2011, 71, 281-288.	1.2	224
101	DNA fusion gene vaccines induce cytotoxic Tâ€cell attack on naturally processed peptides of human prostateâ€specific membrane antigen. European Journal of Immunology, 2011, 41, 2447-2456.	1.6	15
102	Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature. Modern Pathology, 2011, 24, 1521-1529.	2.9	60
103	GAD1 is a biomarker for benign and malignant prostatic tissue. Scandinavian Journal of Urology and Nephrology, 2011, 45, 39-45.	1.4	16
104	Prostate-Specific Membrane Antigen-Based Therapeutics. Advances in Urology, 2012, 2012, 1-9.	0.6	74
105	Landmarks in prostate cancer diagnosis: the biomarkers. BJU International, 2012, 110, 8-13.	1.3	28
106	Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities. Science, 2012, 338, 903-910.	6.0	1,166
107	Integrative Analysis of N-Linked Human Glycoproteomic Data Sets Reveals PTPRF Ectodomain as a Novel Plasma Biomarker Candidate for Prostate Cancer. Journal of Proteome Research, 2012, 11, 2653-2665.	1.8	18
108	Isolation and characterization of circulating tumor cells in prostate cancer. Frontiers in Oncology, 2012, 2, 131.	1.3	38
109	Prostate-specific membrane antigen: a new potential prognostic marker of osteosarcoma. Medical Oncology, 2012, 29, 2234-2239.	1.2	22
110	Functional Characterization of Circulating Tumor Cells with a Prostate-Cancer-Specific Microfluidic Device. PLoS ONE, 2012, 7, e35976.	1.1	185

#	Article	IF	Citations
111	The APC/C Ubiquitin Ligase: From Cell Biology to Tumorigenesis. Frontiers in Oncology, 2011, 1, 60.	1.3	44
112	Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices. Biomedical Microdevices, 2012, 14, 401-407.	1.4	42
113	Nuclear Medicine Therapy. , 2013, , .		5
114	Antibodyâ€“Drug Conjugate Target Selection: Critical Factors. Methods in Molecular Biology, 2013, 1045, 29-40.	0.4	43
115	PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 486-495.	3.3	773
116	Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer. World Journal of Urology, 2013, 31, 1327-1332.	1.2	12
117	Translational Molecular Imaging of Prostate Cancer. Current Radiology Reports, 2013, 1, 216-226.	0.4	14
118	Prostate-Specific Membrane Antigen Protein Expression in Tumor Tissue and Risk of Lethal Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 2354-2363.	1.1	99
119	Radioimmunotherapy of Prostate Carcinoma. , 2013, , 265-277.		0
120	First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer. Journal of Nuclear Medicine, 2013, 54, 380-387.	2.8	201
121	Anti-PSMA Antibody-Drug Conjugates and Immunotoxins. , 2013, , 255-272.		0
122	Anti-PSMA antibody-coupled gold nanorods detection by optical and electron microscopies. Micron, 2013, 50, 68-74.	1.1	7
123	Prostate Specific Membrane Antigen-Based Therapeutics. , 2013, , 459-466.		0
124	Molecular Imaging in Diagnostics. , 2013, , 193-205.		0
125	Prostate-specific membrane antigen-based imaging. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 144-154.	0.8	96
126	A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. European Journal of Cancer, 2013, 49, 2223-2232.	1.3	47
127	A Multivalent Approach of Imaging Probe Design To Overcome an Endogenous Anion Binding Competition for Noninvasive Assessment of Prostate Specific Membrane Antigen. Molecular Pharmaceutics, 2013, 10, 2975-2985.	2.3	11
128	Antibody-Drug Conjugates and Immunotoxins. , 2013, , .		5

#	Article	IF	Citations
129	Molecularly Targeted Agents as Radiosensitizers in Cancer Therapyâ€"Focus on Prostate Cancer. International Journal of Molecular Sciences, 2013, 14, 14800-14832.	1.8	34
130	Next-generation therapy for residual prostate cancer. Immunotherapy, 2013, 5, 1235-1241.	1.0	1
131	Angiogenesis Inhibitors in the Treatment of Prostate Cancer. Chemical Immunology and Allergy, 2014, 99, 197-215.	1.7	7
132	Targeted Radionuclide Therapy of Prostate Cancer. Medical Radiology, 2013, , 617-628.	0.0	0
133	Antibody-drug conjugates targeting prostate-specific membrane antigen. Frontiers in Bioscience - Landmark, 2014, 19, 12.	3.0	18
135	Re: Antibody-drug Conjugates Targeting Prostate-specific Membrane Antigen. European Urology, 2014, 66, 1190-1193.	0.9	5
136	The utility of PSMA and PSA immunohistochemistry in the cytologic diagnosis of metastatic prostate carcinoma. Diagnostic Cytopathology, 2014, 42, 570-575.	0.5	20
137	Development of a polymer theranostic for prostate cancer. Polymer Chemistry, 2014, 5, 6932-6942.	1.9	53
138	Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA). EJNMMI Research, 2014, 4, 13.	1.1	41
139	Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 11-20.	3.3	817
140	Preclinical evaluation of BAY 1075553, a novel 18F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 89-101.	3.3	36
141	Molecular Imaging of Urogenital Diseases. Seminars in Nuclear Medicine, 2014, 44, 93-109.	2.5	30
142	^{99m}Tc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2014, 55, 1791-1798.	2.8	125
143	Targeted Inhibition of Prostate Cancer Metastases with an RNA Aptamer to Prostate-specific Membrane Antigen. Molecular Therapy, 2014, 22, 1910-1922.	3.7	91
144	Ultra-effective photothermal therapy for prostate cancer cells using dual aptamer-modified gold nanostars. Journal of Materials Chemistry B, 2014, 2, 4862-4867.	2.9	41
145	Management of Castration Resistant Prostate Cancer. Current Clinical Urology, 2014, , .	0.0	2
146	Prostate cancer relevant antigens and enzymes for targeted drug delivery. Journal of Controlled Release, 2014, 187, 118-132.	4.8	86
149	PSMA Expression is Highly Homogenous in Primary Prostate Cancer. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 449-455.	0.6	33

#	Article	IF	Citations
150	Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists. Radiation Oncology, 2015, 10, 233.	1.2	74
151	Metastatic Poorly Differentiated Prostatic Carcinoma With Neuroendocrine Differentiation. Clinical Nuclear Medicine, 2015, 40, e163-e166.	0.7	69
152	Detection of Brain Metastasis With 68Ga-Labeled PSMA Ligand PET/CT. Clinical Nuclear Medicine, 2015, 40, 328-329.	0.7	49
153	Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody. Current Radiopharmaceuticals, 2015, 9, 44-53.	0.3	70
154	Prostateâ€specific membrane antigenâ€based imaging in prostate cancer: Impact on clinical decision making process. Prostate, 2015, 75, 748-757.	1.2	59
155	Prostate Gland. , 2015, , 397-420.		2
156	⁶⁸Ga- and ¹⁷⁷Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. Journal of Nuclear Medicine, 2015, 56, 1169-1176.	2.8	432
157	Biodistribution and Radiation Dosimetry for a Probe Targeting Prostate-Specific Membrane Antigen for Imaging and Therapy. Journal of Nuclear Medicine, 2015, 56, 855-861.	2.8	122
158	Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. Journal of Nuclear Medicine, 2015, 56, 668-674.	2.8	907
159	Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Research, 2015, 5, 28.	1.1	63
160	¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. Journal of Nuclear Medicine, 2015, 56, 1003-1010.	2.8	180
162	The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 197-209.	3.3	866
163	Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma. Journal of Pathology and Translational Medicine, 2016, 50, 345-354.	0.4	38
164	Marked Response to 177Lu Prostate-Specific Membrane Antigen Treatment in Patient With Metastatic Prostate Cancer. Clinical Nuclear Medicine, 2016, 41, 159-160.	0.7	10
165	Prostate-specific membrane antigen positron emission tomography in prostate cancer. Current Opinion in Oncology, 2016, 28, 216-221.	1.1	45
166	Small Molecules for Active Targeting in Cancer. Medicinal Research Reviews, 2016, 36, 494-575.	5.0	107
167	⁶⁸Gaâ€PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU International, 2016, 117, 732-739.	1.3	239
168	Widespread Metastatic Prostate Carcinoma Shown by 68Ga-PSMA PET/CT. Clinical Nuclear Medicine, 2016, 41, e294-e295.	0.7	6

#	Article	IF	Citations
169	Seyferthâ€“Gilbert Homologation as a Route to ¹⁸Fâ€Labeled Building Blocks: Preparation of RadiofluorÂinated Phenylacetylenes and Their Application in PET Chemistry. European Journal of Organic Chemistry, 2016, 2016, 430-433.	1.2	10
170	Biodistribution and radiation dosimetry of 68Ga-PSMA HBED CCâ€”a PSMA specific probe for PET imaging of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1962-1970.	3.3	66
171	Systemic Radioligand Therapy with ¹⁷⁷ Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. Journal of Urology, 2016, 196, 382-391.	0.2	166
172	Preclinical Comparative Study of ⁶⁸Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA. Bioconjugate Chemistry, 2016, 27, 1447-1455.	1.8	54
173	Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology. Molecular Therapy, 2016, 24, 1267-1277.	3.7	88
174	PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer and Prostatic Diseases, 2016, 19, 223-230.	2.0	121
175	PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. Colloids and Surfaces B: Biointerfaces, 2016, 144, 8-20.	2.5	106
176	PSMA PET and Radionuclide Therapy in Prostate Cancer. Seminars in Nuclear Medicine, 2016, 46, 522-535.	2.5	82
178	Prostate-Specific Membrane Antigenâ€“Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 90S-96S.	2.8	48
179	The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 79S-89S.	2.8	200
180	Bombesin-Targeted PET of Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 67S-72S.	2.8	43
182	Prostate-Specific Membrane Antigen (PSMA) Avid Pancreatic Neuroendocrine Tumor. Clinical Nuclear Medicine, 2016, 41, 804-806.	0.7	42
183	Nonâ€“Prostate-Specific Membrane Antigen-Avid Metastatic Lung Nodule From Primary Prostatic Adenocarcinoma. Clinical Nuclear Medicine, 2016, 41, 776-778.	0.7	12
184	Prostate-Specific Membrane Antigen Uptake in Small Cleaved B-Cell Follicular Non-Hodgkin Lymphoma. Clinical Nuclear Medicine, 2016, 41, 980-981.	0.7	19
185	Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1611-1620.	3.3	143
186	Nuclear Medicine Imaging of Prostate Cancer. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2016, 188, 1037-1044.	0.7	9
187	Diagnostic Efficacy of ⁶⁸ Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. Journal of Urology, 2016, 195, 1436-1443.	0.2	659
188	Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 557-562.	2.8	155

#	Article	IF	Citations
189	Small-molecule PSMA ligands. Current state, SAR and perspectives. Journal of Drug Targeting, 2016, 24, 679-693.	2.1	40
190	The Utility of Molecular Imaging in Prostate Cancer. Current Urology Reports, 2016, 17, 26.	1.0	15
191	Identifying cancer origin using circulating tumor cells. Cancer Biology and Therapy, 2016, 17, 430-438.	1.5	56
192	Molecular Imaging of Prostate Cancer. Radiographics, 2016, 36, 142-159.	1.4	83
193	Comparison of Prostate-Specific Membrane Antigenâ€"Based ¹⁸F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-NaÃ¯ve and Castration-Resistant Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 46-53.	2.8	111
194	Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 70-83.	3.3	148
195	Initial Experience of 68Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. European Urology, 2016, 69, 393-396.	0.9	368
196	Prospective evaluation of 68Galliumâ€prostateâ€specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU International, 2017, 119, 209-215.	1.3	263
197	Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade. Molecular Therapy - Oncolytics, 2017, 4, 41-54.	2.0	74
198	Management of Prostate Cancer. , 2017, , .		5
199	68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 941-949.	3.3	247
200	Optimization of Labeling PSMA^{HBED} with Ethanol-Postprocessed ⁶⁸Ga and Its Quality Control Systems. Journal of Nuclear Medicine, 2017, 58, 432-437.	2.8	14
201	Clinical Experience with 18F-Labeled Small Molecule Inhibitors of Prostate-Specific Membrane Antigen. PET Clinics, 2017, 12, 235-241.	1.5	13
202	New frontiers in prostate cancer imaging: clinical utility of prostate-specific membrane antigen positron emission tomography. International Urology and Nephrology, 2017, 49, 803-810.	0.6	3
203	99m Tc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen. Nuclear Medicine and Biology, 2017, 48, 69-75.	0.3	38
204	⁶⁸Ga or¹⁸F for Prostate Cancer Imaging?. Journal of Nuclear Medicine, 2017, 58, 687-688.	2.8	105
205	Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1258-1268.	3.3	425
206	Diagnostic Accuracy of 64 Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience. Urology, 2017, 106, 139-145.	0.5	42

#	Article	IF	Citations
207	Evaluation of Practical Interpretation Hurdles in 68Ga-PSMA PET/CT in 55 Patients. Clinical Nuclear Medicine, 2017, 42, e322-e327.	0.7	32
208	Radical Prostatectomy for High-risk Localized or Node-Positive Prostate Cancer: Removing the Primary. Current Urology Reports, 2017, 18, 53.	1.0	7
209	Near-Infrared Photoimmunotherapy Targeting Prostate Cancer with Prostate-Specific Membrane Antigen (PSMA) Antibody. Molecular Cancer Research, 2017, 15, 1153-1162.	1.5	69
210	68 Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends. Prostate International, 2017, 5, 125-129.	1.2	36
211	Prostate-specific membrane antigenâ€"directed nanoparticle targeting for extreme nearfield ablation of prostate cancer cells. Tumor Biology, 2017, 39, 101042831769594.	0.8	13
212	Managing Cancer Relapse After Radical Prostatectomy. Urologic Clinics of North America, 2017, 44, 597-609.	0.8	1
213	Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer. Nuclear Medicine Communications, 2017, 38, 1094-1102.	0.5	44
214	Targeting strategies of adenovirus-mediated gene therapy and virotherapy for prostate cancer. Molecular Medicine Reports, 2017, 16, 6443-6458.	1.1	10
215	Approaches to Multireceptor Targeting: Hybrid Radioligands, Radioligand Cocktails, and Sequential Radioligand Applications. Journal of Nuclear Medicine, 2017, 58, 10S-16S.	2.8	36
216	Glu-Ureidoâ€"Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers. Journal of Nuclear Medicine, 2017, 58, 17S-26S.	2.8	111
217	Incidental PSMA Uptake in an Undisplaced Fracture of a Vertebral Body. Clinical Nuclear Medicine, 2017, 42, 465-466.	0.7	24
218	A 99mTc-labelled scFv antibody fragment that binds to prostate-specific membrane antigen. Nuclear Medicine Communications, 2017, 38, 666-671.	0.5	20
219	PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 13655-13660.	3.3	10
220	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2017, , 883-923.		0
221	First Experience With SPECT/CT Using a 99mTc-Labeled Inhibitor for Prostate-Specific Membrane Antigen in Patients With Biochemical Recurrence of Prostate Cancer. Clinical Nuclear Medicine, 2017, 42, 26-33.	0.7	37
222	A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). BMC Cancer, 2017, 17, 453.	1.1	83
223	Incidental Prostate-Specific Membrane Antigen Uptake in a Peripheral Nerve Sheath Tumor. Clinical Nuclear Medicine, 2017, 42, 560-562.	0.7	17
224	Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 92-101.	3.3	237

#	Article	IF	Citations
225	Development of prostate specific membrane antigen targeted ultrasound microbubbles using bioorthogonal chemistry. PLoS ONE, 2017, 12, e0176958.	1.1	14
226	Investigation of the halo-artifact in 68Ga-PSMA-11-PET/MRI. PLoS ONE, 2017, 12, e0183329.	1.1	53
227	Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy. Radiation Oncology, 2017, 12, 176.	1.2	34
228	Characterization of prostate cancer cell progression in zebrafish xenograft model. International Journal of Oncology, 2018, 52, 252-260.	1.4	17
229	Integrated 68Ga-HBED-CC-PSMAPET/MRI in patients with suspected recurrent prostate cancer. Nuklearmedizin - NuclearMedicine, 2017, 56, 73-81.	0.3	19
230	Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials. Critical Reviews in Oncology/Hematology, 2018, 123, 7-20.	2.0	89
232	Molecular Profiling of Pooled Circulating Tumor Cells from Prostate Cancer Patients Using a Dual-Antibody-Functionalized Microfluidic Device. Analytical Chemistry, 2018, 90, 3744-3751.	3.2	46
233	Incidental Detection of Basaloid Thymic Carcinoma With 68Ga-PSMA-11 PET/CT in a Patient With Recurrent Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, e497-e499.	0.9	3
234	PET/MR Imaging: Current and Emerging Applications. , 2018, , .		4
235	Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy. Molecular Pharmaceutics, 2018, 15, 2297-2306.	2.3	97
236	Loss of PSMA Expression in Non-neuroendocrine Dedifferentiated Acinar Prostate Cancer. Clinical Nuclear Medicine, 2018, 43, 526-528.	0.7	21
237	Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA). Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 1407-1416.	1.7	61
238	Imaging prostate cancer (PCa) with [^{99m}Tc(CO)₃]finasteride dithiocarbamate. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 550-556.	0.5	4
239	Molecular Imaging of Prostate Cancer: Radiopharmaceuticals for Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT). Molecular Pathology Library, 2018, , 475-501.	0.1	2
240	68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. World Journal of Urology, 2018, 36, 519-527.	1.2	137
241	Automated radiosynthesis of Al[18 F]PSMA-11 for large scale routine use. Applied Radiation and Isotopes, 2018, 135, 19-27.	0.7	28
242	68Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1852-1861.	3.3	54
243	18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1329-1334.	3.3	59

#	Article	IF	Citations
244	PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. Scientific Reports, 2018, 8, 4254.	1.6	128
246	Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging. Journal of Nuclear Medicine, 2018, 59, 486-493.	2.8	27
247	The use of PET/CT in prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 4-21.	2.0	70
248	Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. Journal of Experimental Medicine, 2018, 215, 159-175.	4.2	121
249	Repeated ¹⁷⁷Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq. Journal of Nuclear Medicine, 2018, 59, 459-465.	2.8	68
250	Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents. Translational Andrology and Urology, 2018, 7, 831-843.	0.6	35
251	Integration of PSMA-targeted PET imaging into the armamentarium for detecting clinically significant prostate cancer. Current Opinion in Urology, 2018, 28, 493-498.	0.9	8
252	Clinical implications of PET/CT in prostate cancer management. Translational Andrology and Urology, 2018, 7, 844-854.	0.6	20
253	68Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients. Nuclear Medicine Communications, 2018, 39, 871-880.	0.5	5
254	ExoAPP: Exosome-Oriented, Aptamer Nanoprobe-Enabled Surface Proteins Profiling and Detection. Analytical Chemistry, 2018, 90, 14402-14411.	3.2	158
255	Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for ⁶⁴Cu-Based PET Imaging. Molecular Pharmaceutics, 2018, 15, 5556-5564.	2.3	28
256	Comparative study between ⁶⁸Gaâ€prostateâ€specific membrane antigen positron emission tomography and conventional imaging in the initial staging of prostate cancer. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 816-822.	0.9	23
257	Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer. Radiology, 2018, 288, 495-505.	3.6	97
258	68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2035-2044.	3.3	72
259	The theranostic target prostate-specific membrane antigen is expressed in medullary thyroid cancer. Human Pathology, 2018, 81, 245-254.	1.1	14
260	PET/CT With 68Ga-PSMA in Prostate Cancer: Radiopharmaceutical Background and Clinical Implications. Current Radiopharmaceuticals, 2018, 11, 4-13.	0.3	28
261	Current Advances in Aptamers for Cancer Diagnosis and Therapy. Cancers, 2018, 10, 9.	1.7	139
262	Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2045-2054.	3.3	116

#	Article	IF	Citations
263	Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2055-2061.	3.3	102
264	[177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncology, The, 2018, 19, 825-833.	5.1	823
265	68Ga-PSMA and 11C-Choline comparison using a tri-modality PET/CT-MRI (3.0ÂT) system with a dedicated shuttle. European Journal of Hybrid Imaging, 2018, 2, 9.	0.6	17
266	68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5Âng/ml. Efficacy and impact on treatment strategy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 11-19.	3.3	96
267	New approaches for effective and safe pelvic radiotherapy in high-risk prostate cancer. Nature Reviews Urology, 2019, 16, 523-538.	1.9	21
268	Imaging CAR T cell therapy with PSMA-targeted positron emission tomography. Science Advances, 2019, 5, eaaw5096.	4.7	87
269	Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer. Pharmaceutics, 2019, 11, 358.	2.0	17
270	A pilot study of prostateâ€specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. Prostate, 2019, 79, 1597-1603.	1.2	18
271	ï»¿68Ga-RM2 PET in PSMA- positive and -negative prostate cancer patients. Nuklearmedizin - NuclearMedicine, 2019, 58, 352-362.	0.3	9
272	Prostate cancer and inflammation: A new molecular imaging challenge in the era of personalized medicine. Nuclear Medicine and Biology, 2019, 68-69, 66-79.	0.3	19
273	Imaging of Prostate-Specific Membrane Antigen with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical Applications. Annual Review of Medicine, 2019, 70, 461-477.	5.0	50
274	[177Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative In Vitro Autoradiography. Pharmaceuticals, 2019, 12, 18.	1.7	41
275	Detection rates of recurrent prostate cancer: ⁶⁸Gallium (Ga)-labelled prostate-specific membrane antigen versus choline PET/CT scans. A systematic review. Therapeutic Advances in Urology, 2019, 11, 175628721881579.	0.9	18
276	Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1919-1930.	3.3	109
277	Phage display screening of therapeutic peptide for cancer targeting and therapy. Protein and Cell, 2019, 10, 787-807.	4.8	163
278	Comparison of prostateâ€specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer. Cancer Reports, 2019, 2, e1169.	0.6	17
279	A Novel Fully Human Antibody targeting Extracellular Domain of PSMA Inhibits Tumor Growth in Prostate Cancer. Molecular Cancer Therapeutics, 2019, 18, 1289-1301.	1.9	8
280	Radiation Dosimetry and Biodistribution of ¹⁸F-PSMA-11 for PET Imaging of Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 1736-1742.	2.8	34

#	Article	IF	Citations
281	Lu177â€<scp>PSMA</scp> therapy for men with advanced prostate cancer: Initial 18 months experience at a single Australian tertiary institution. Journal of Medical Imaging and Radiation Oncology, 2019, 63, 538-545.	0.9	25
282	DNA damage in blood leucocytes of prostate cancer patients during therapy with 177Lu-PSMA. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1723-1732.	3.3	13
283	Molecular Imaging of Recurrent and Metastatic Prostate Cancer. Seminars in Nuclear Medicine, 2019, 49, 280-293.	2.5	12
284	Recent advances in extracellular vesicle research for urological cancers: From technology to application. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 342-360.	3.3	16
285	Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer. Theranostics, 2019, 9, 1247-1263.	4.6	39
286	Safety Profile and Therapeutic Efficacy of One Cycle of Lu177-PSMA in End-Stage Metastatic Castration-Resistant Prostate Cancer Patients with Low Performance Status. Nuclear Medicine and Molecular Imaging, 2019, 53, 423-431.	0.6	10
287	Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments. European Urology Oncology, 2019, 2, 152-162.	2.6	29
288	68Ga PSMA PET-CT: New Hope in Prostate Cancer Imaging and Therapy. Bangladesh Journal of Nuclear Medicine, 2019, 22, 53-57.	0.0	0
289	Does lymph node localization affect prostate-specific membrane antigen uptake?. Nuclear Medicine Communications, 2019, 40, 835-841.	0.5	0
290	68Ga-prostate-specific membrane antigen PETCT-based response to androgen deprivation therapy in patients with prostate cancer. Nuclear Medicine Communications, 2019, 40, 1283-1288.	0.5	3
291	Expression of Prostate-Specific Membrane Antigen in Tumor-Associated Vasculature Predicts Poor Prognosis in Hepatocellular Carcinoma. Clinical and Translational Gastroenterology, 2019, 10, e00041.	1.3	44
292	High negative predictive value of 68Ga PSMA PET-CT for local lymph node metastases in high risk primary prostate cancer with histopathological correlation. Cancer Imaging, 2019, 19, 86.	1.2	11
293	Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions â€œinvisibleâ€•on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 20-30.	3.3	79
294	Efficacy of early imaging with 68Ga-PSMA I&T in the discrimination of pelvic lesions in prostate cancer patients. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2019, 38, 100-105.	0.1	0
295	Eficacia de la imagen precoz con 68Ga-PSMA-I&T para la discriminaciÃ³n de lesiones en los pacientes con cÃ¡ncer de prÃ³stata. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2019, 38, 100-105.	0.0	1
296	PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics. World Journal of Urology, 2019, 37, 1255-1261.	1.2	37
297	Evaluation of ¹¹¹In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen. Journal of Nuclear Medicine, 2019, 60, 400-406.	2.8	19
298	Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis. Urologia Internationalis, 2019, 102, 27-36.	0.6	45

#	Article	IF	Citations
299	Radiopharmaceuticals. , 2020, , .		3
300	Nonneoplastic Diseases of the Prostate. , 2020, , 358-414.e13.		0
301	Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of ¹⁷⁷Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 857-865.	2.8	191
302	68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancerâ€"a modified protocol compared with the common protocol. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 624-631.	3.3	26
303	Use of galliumâ€68 prostateâ€specific membrane antigen positronâ€emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature. BJU International, 2020, 125, 206-214.	1.3	80
304	The effect of androgen deprivation therapy on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 632-641.	3.3	27
305	Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity. Theranostics, 2020, 10, 1678-1693.	4.6	52
306	Online Prostate-Specific Membrane Antigen and Positron Emission Tomographyâ€"Guided Radiation Therapy for Oligometastatic Prostate Cancer. Advances in Radiation Oncology, 2020, 5, 260-268.	0.6	13
307	Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer. Current Opinion in Urology, 2020, 30, 98-105.	0.9	22
308	Impact of 68Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 652-664.	3.3	38
309	Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC). Cancers, 2020, 12, 2831.	1.7	12
310	A Direct Comparison between the Lateral Magnetophoretic Microseparator and AdnaTest for Isolating Prostate Circulating Tumor Cells. Micromachines, 2020, 11, 870.	1.4	7
311	A comparison between 68Ga-labeled prostate-specific membrane antigen-PET/CT and multiparametric MRI for excluding regional metastases prior to radical prostatectomy. Abdominal Radiology, 2020, 45, 4194-4201.	1.0	7
312	Preclinical evaluation of ²¹³Bi-/²²⁵Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer. Journal of Nuclear Medicine, 2021, 62, jnumed.120.256388.	2.8	17
313	Prospective evaluation of 68Ga-PSMA-11 PET/CT in Chinese men with biochemical recurrence after radical prostatectomy for prostate cancer: relationships between location of recurrence, time after prostatectomy, and serum PSA level. Medical Oncology, 2020, 37, 89.	1.2	5
314	A Walk with Lu-177 PSMA: How Close we Have Reached from Bench to Bedside?. Cancer Investigation, 2020, 38, 486-492.	0.6	5
315	Position of Circulating Tumor Cells in the Clinical Routine in Prostate Cancer and Breast Cancer Patients. Cancers, 2020, 12, 3782.	1.7	7
317	Salvage Pelvic Lymph Node Dissection and Current State of Imaging for Recurrent Prostate Cancer: Does a Standard Exist?. Current Urology Reports, 2020, 21, 62.	1.0	2

#	Article	IF	Citations
319	Does bone scintigraphy still have a role in the era of 68ÂGa-PSMA PET/CT in prostate cancer?. Annals of Nuclear Medicine, 2020, 34, 476-485.	1.2	15
320	Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with ‹sup›68‹/sup›Ga-PSMA-11-PET. Theranostics, 2020, 10, 6082-6094.	4.6	46
321	Combined Application of Albumin-Binding [177Lu]Lu-PSMA-ALB-56 and Fast-Cleared PSMA Inhibitors: Optimization of the Pharmacokinetics. Molecular Pharmaceutics, 2020, 17, 2044-2053.	2.3	12
322	Multifaceted Bioanalytical Methods for the Comprehensive Pharmacokinetic and Catabolic Assessment of MEDI3726, an Anti-Prostate-Specific Membrane Antigen Pyrrolobenzodiazepine Antibodyâ€“Drug Conjugate. Analytical Chemistry, 2020, 92, 11135-11144.	3.2	15
323	PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy. Cancers, 2020, 12, 1367.	1.7	75
324	Impact of PSMA PET/CT in prostate cancer patientâ€™s clinical management: a pictorial essay of interesting cases with histologic confirmation. Clinical and Translational Imaging, 2020, 8, 207-226.	1.1	2
325	Prostate MRI Essentials. , 2020, , .		1
327	Comparison of 68Ga-PSMA-11 PET/CT with 11C-acetate PET/CT in re-staging of prostate cancer relapse. Scientific Reports, 2020, 10, 4993.	1.6	9
328	Retrospective correlation of 68ga-psma uptake with clinical parameters in prostate cancer patients undergoing definitive radiotherapy. Annals of Nuclear Medicine, 2020, 34, 388-396.	1.2	8
329	68Ga-labeled PSMA-11Â(68Ga-isoPROtrace-11) synthesized with ready to use kit: normal biodistribution and uptake characteristics of tumour lesions. Scientific Reports, 2020, 10, 3109.	1.6	17
330	Molecular Imaging of Newly Diagnosed Prostate Cancer. Cancer Journal (Sudbury, Mass), 2020, 26, 43-47.	1.0	4
331	Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer. Scientific Reports, 2020, 10, 2705.	1.6	17
332	Comparison of Prostate-Specific Membrane Antigen Expression Levels in Human Salivary Glands to Non-Human Primates and Rodents. Cancer Biotherapy and Radiopharmaceuticals, 2020, 35, 284-291.	0.7	18
333	Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer. PLoS ONE, 2020, 15, e0226219.	1.1	26
334	Real time ultrasound molecular imaging of prostate cancer with PSMA-targeted nanobubbles. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 28, 102213.	1.7	41
335	A prospective intra-individual comparison of [68Ga]Ga-PSMA-11 PET/CT, [68Ga]Ga-NODAGAZOL PET/CT, and [99mTc]Tc-MDP bone scintigraphy for radionuclide imaging of prostate cancer skeletal metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 134-142.	3.3	23
336	Detection of metastases in newly diagnosed prostate cancer by using 68Ga-PSMA PET/CT and its relationship with modified Dâ€™Amico risk classification. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1639-1649.	3.3	11
337	The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature. European Urology Oncology, 2021, 4, 370-395.	2.6	25

#	Article	IF	Citations
338	Exceptional initial response of prostate cancer lung metastases to 225Ac-PSMA: A case report. Current Problems in Cancer Case Reports, 2021, 3, 100038.	0.1	2
339	Multigene model for predicting metastatic prostate cancer using circulating tumor cells by microfluidic magnetophoresis. Cancer Science, 2021, 112, 859-870.	1.7	11
340	A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization. Prostate Cancer and Prostatic Diseases, 2021, 24, 220-232.	2.0	3
341	Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 893-903.	3.3	36
343	Targeted micelles with chemotherapeutics and gene drugs to inhibit the G1/S and G2/M mitotic cycle of prostate cancer. Journal of Nanobiotechnology, 2021, 19, 17.	4.2	26
344	Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring. Theranostics, 2021, 11, 6800-6817.	4.6	21
345	Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies. Cancer Research, 2021, 81, 2234-2245.	0.4	11
346	Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer. Current Oncology Reports, 2021, 23, 59.	1.8	9
348	Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer. Targeted Oncology, 2021, 16, 369-380.	1.7	21
349	Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules. Journal of Nuclear Medicine, 2021, 62, 1461-1467.	2.8	9
350	Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?. Annals of Nuclear Medicine, 2021, 35, 680-690.	1.2	11
351	Critical Role of 2-[18F]-fluoro-2-deoxy-glucose in Hormonally Active Malignancies. PET Clinics, 2021, 16, 177-189.	1.5	1
352	Standardization of the [68Ga]Ga-PSMA-11 Radiolabeling Protocol in an Automatic Synthesis Module: Assessments for PET Imaging of Prostate Cancer. Pharmaceuticals, 2021, 14, 385.	1.7	13
353	The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizerâ€”a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report. Nuclear Medicine and Molecular Imaging, 2021, 55, 136-140.	0.6	7
354	The Establishment of New Thresholds for PLND-Validated Clinical Nomograms to Predict Non-Regional Lymph Node Metastases: Using 68Ga-PSMA PET/CT as References. Frontiers in Oncology, 2021, 11, 658669.	1.3	4
355	PET Molecular Imaging: A Holistic Review of Current Practice and Emerging Perspectives for Diagnosis, Therapeutic Evaluation and Prognosis in Clinical Oncology. International Journal of Molecular Sciences, 2021, 22, 4159.	1.8	41
356	Optimized Application of 68Ga-Prostate-Specific Membrane Antigen-617 Whole-Body PET/CT and Pelvic PET/MR in Prostate Cancer Initial Diagnosis and Staging. Frontiers in Medicine, 2021, 8, 657619.	1.2	3
357	More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond. Cancers, 2021, 13, 2244.	1.7	12

#	Article	IF	Citations
358	Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e190-e202.	1.8	9
359	Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management. Cancers, 2021, 13, 3556.	1.7	9
360	Assessment of volumetric parameters derived from 68Ga-PSMA PET/CT in prostate cancer patients with biochemical recurrence: an institutional experience. Nuclear Medicine Communications, 2021, 42, 1254-1260.	0.5	7
361	68Ga-PSMA PET/CT and mpMRI for primary lymph node staging of intermediate to high-risk prostate cancer: a systematic review and meta-analysis of diagnostic test accuracy. Clinical and Translational Imaging, 2021, 9, 523-537.	1.1	3
362	Is Hypoxia a Factor Influencing PSMA-Directed Radioligand Therapy?â€"An In Silico Study on the Role of Chronic Hypoxia in Prostate Cancer. Cancers, 2021, 13, 3429.	1.7	8
363	Competitive blocking of salivary gland [18F]DCFPyL uptake via localized, retrograde ductal injection of non-radioactive DCFPyL: a preclinical study. EJNMMI Research, 2021, 11, 66.	1.1	6
364	PSMA Expression in Differentiated Thyroid Cancer: Association with Radioiodine, 18FDG Uptake, and Patient Outcome. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3536-3545.	1.8	7
365	Photodynamic Therapy of Melanoma B16 with Chlorin E6 Conjugated with a PSMA-Ligand. Bulletin of Experimental Biology and Medicine, 2021, 171, 468-471.	0.3	7
366	How accurate is 68Gallium-prostate specific membrane antigen positron emission tomography / computed tomography (68Ga-PSMA PET/CT) on primary lymph node staging before radical prostatectomy in intermediate and high risk prostate cancer? A study of patient- and lymph node- based analyses. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 6.e1-6.e9.	0.8	4
367	A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand. Science Advances, 2021, 7, .	4.7	20
368	Prostate-Specific Membrane Antigen (PSMA) PET: A Counterpart to Prostate MRI. Seminars in Roentgenology, 2021, 56, 376-383.	0.2	0
369	177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study). European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1075-1085.	3.3	37
370	In vitro and in vivo comparative study of a novel 68Ga-labeled PSMA-targeted inhibitor and 68Ga-PSMA-11. Scientific Reports, 2021, 11, 19122.	1.6	4
371	Lutetium-177â€"PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2021, 385, 1091-1103.	13.9	1,042
372	The role of histopathological and biochemical parameters for predicting metastatic disease on 68 Gaâ€PSMAâ€11 PET in prostate cancer. Prostate, 2021, 81, 1337-1348.	1.2	3
373	Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. Current Oncology, 2021, 28, 3692-3704.	0.9	5
374	Comparison of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography for Primary Staging of Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Open Science, 2021, 33, 61-71.	0.2	7
375	Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow. Physics in Medicine and Biology, 2021, 66, 035016.	1.6	17

#	Article	IF	Citations
376	Establishment and prospective validation of an SUV_{max} cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by ⁶⁸Ga-PSMA PET/CT: a real-world study. Theranostics, 2021, 11, 8396-8411.	4.6	24
377	PET/CT and PET/MRI, Normal Variations, and Artifacts. , 2020, , 549-584.		2
378	68Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?. Wiener Medizinische Wochenschrift, 2019, 169, 3-11.	0.5	14
379	Comparison of MRI, PSMA PET/CT, and Fusion PSMA PET/MRI for Detection of Clinically Significant Prostate Cancer. Journal of Computer Assisted Tomography, 2021, 45, 210-217.	0.5	15
381	Day-to-day variability of [68Ga]Ga-PSMA-11 accumulation in primary prostate cancer: effects on tracer uptake and visual interpretation. EJNMMI Research, 2020, 10, 132.	1.1	12
382	Optimization of PET protocol and interrater reliability of 18F-PSMA-11 imaging of prostate cancer. EJNMMI Research, 2020, 10, 14.	1.1	13
383	Optimization of injected 68Ga-PSMA activity based on list-mode phantom data and clinical validation. EJNMMI Physics, 2020, 7, 20.	1.3	5
384	Automated synthesis and quality control of [99mTc]Tc-PSMA for radioguided surgery (in a) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	1.8	10
385	Uptake of [18F]DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in the Clinical Interpretation of PSMA PET Studies. Tomography, 2015, 1, 81-84.	0.8	31
386	Pitfalls in Gallium-68 PSMA PET/CT Interpretationâ€"A Pictorial Review. Tomography, 2018, 4, 182-193.	0.8	86
387	A novel anti-PSMA human scFv has the potential to be used as a diagnostic tool in prostate cancer. Oncotarget, 2016, 7, 59471-59481.	0.8	23
388	68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients. Oncotarget, 2017, 8, 12247-12258.	0.8	21
389	PSMA-homing dsRNA chimeric protein vector kills prostate cancer cells and activates anti-tumor bystander responses. Oncotarget, 2017, 8, 24046-24062.	0.8	6
390	Targeting Tumors with Small Molecule Peptides. Current Cancer Drug Targets, 2016, 16, 489-508.	0.8	22
391	Overview of Tumor-Associated Antigens (TAAs) as Potential Therapeutic Targets for Prostate Cancer Therapy. Current Cancer Therapy Reviews, 2008, 4, 271-284.	0.2	2
392	Comparison of Bone Uptake in Bone Scan and Ga-68 PSMA PET/CT Images in Patients with Prostate Cancer. Current Medical Imaging, 2019, 15, 589-594.	0.4	5
393	⁶⁸Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership. Journal of Nuclear Medicine, 2021, 62, 149-155.	2.8	74
394	Assessment of biochemical recurrence of prostate cancer (Review). International Journal of Oncology, 2019, 55, 1194-1212.	1.4	14

#	Article	IF	Citations
395	Radioisotopes in management of metastatic prostate cancer. Indian Journal of Urology, 2016, 32, 277.	0.2	4
396	Clinical utility of gallium-68 PSMA PET/CT scan for prostate cancer. Indian Journal of Nuclear Medicine, 2017, 32, 110.	0.1	27
397	Prostate cancer nodal oligometastasis accurately assessed using prostate-specific membrane antigen positron emission tomography-computed tomography and confirmed histologically following robotic-assisted lymph node dissection. Urology Annals, 2016, 8, 255.	0.3	4
398	Can Early Dynamic Positron Emission Tomography/Computed Tomography Obviate the Need for Postdiuresis Image in Ga-PSMA-HBED-CC Scan for Evaluation of Prostate Adenocarcinoma?. Indian Journal of Nuclear Medicine, 2018, 33, 202-208.	0.1	4
399	Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients. World Journal of Nuclear Medicine, 2019, 18, 244-250.	0.3	11
400	Efficacy and safety of177Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: First experience in West Asia â€“ A prospective study. World Journal of Nuclear Medicine, 2019, 18, 258.	0.3	21
401	Differences in the expression of telomerase and prostate-specific membrane antigen in non-advanced prostatic cancer. Folia Histochemica Et Cytobiologica, 2013, 51, 66-72.	0.6	7
402	A novel 5x multiplex immunohistochemical staining reveals PSMA as a helpful marker in prostate cancer with low p504s expression.. Pathology Research and Practice, 2021, 228, 153667.	1.0	5
403	Immunohistology of the Prostate, Bladder, Testis and Kidney. , 2006, , 509-610.		0
404	Novel Biomarkers for Disease Diagnosis, Prognosis, and Prediction. Translational Medicine Series, 2006, , 39-57.	0.0	0
405	Molecular Imaging, Clinical Trial Design, and the Development of Emerging Therapies for Metastatic Prostate Cancer. Translational Medicine Series, 2006, , 291-313.	0.0	0
406	Non-neoplastic diseases of the prostate. , 2008, , 380-440.		3
407	Anti-angiogenic therapy for prostate cancer: rationale and ongoing trials. Clinical Investigation, 2011, 1, 1651-1661.	0.0	0
408	Prostate Cancer: Role of Conventional Radionuclide and Hybrid Bone Imaging. , 2012, , 635-659.		0
409	Tumor Markers. , 2013, , 423-444.		0
410	New Imaging Modalities. Current Clinical Urology, 2014, , 43-63.	0.0	0
411	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2016, , 1-41.		0
412	New Radiopharmaceutical Markers for Metabolism and Receptor. , 2017, , 95-104.		0

#	Article	IF	Citations
413	Postoperative Irradiation: Immediate or Early Delayed?. , 2017, , 231-250.		0
414	Prostate Imaging. , 2018, , 53-61.		0
415	False-positive prostate cancer bone metastases on magnetic resonance imaging correctly classified on gallium-68-prostate-specific membrane antigen positron emission tomography computed tomography. World Journal of Nuclear Medicine, 2018, 17, 305-307.	0.3	2
418	18F-PSMA-1007 PET/CT Performance on Risk Stratification Discrimination and Distant Metastases Prediction in Newly Diagnosed Prostate Cancer. Frontiers in Oncology, 2021, 11, 759053.	1.3	12
419	PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy. Journal of Nuclear Medicine, 2021, 62, 1489-1491.	2.8	11
420	Molecular Imaging of Prostate Cancer. , 2020, , 171-190.		0
421	Development of an Albumin-Based PSMA Probe With Prolonged Half-Life. Frontiers in Molecular Biosciences, 2020, 7, 585024.	1.6	6
422	Selection and Validation of an SUV _{max} Cutoff Value to Discriminate Prostate Cancer From Benign Prostate Hypertrophy by ⁶⁸Ga-PSMA PET/CT: A Real-World Study. SSRN Electronic Journal, 0, , .	0.4	0
423	64Cu-Radiopharmaceuticals. , 2020, , 115-130.		1
424	Clinical outcome of Lu-177 PSMA in metastatic castration-resistant prostate cancer: An initial experience from a tertiary care cancer hospital. Annals of Cancer Research and Therapy, 2020, 28, 156-163.	0.1	0
425	The diagnostic value of PET/CT imaging with the 68Ga-labeled PSMA-ligand in the follow up assessment of prostate cancer after therapy. Egyptian Journal of Radiology and Nuclear Medicine, 2020, 51, .	0.3	0
426	Antimetastatic Gene Therapy. , 2005, , 299-319.		0
427	Recombinant Antibody Candidates for Treatment of Prostate Cancer. , 2007, , 397-410.		2
428	Gene Therapy for Advanced Prostate Cancer. , 2007, , 139-163.		0
429	[68Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study. EJNMMI Research, 2020, 10, 135.	1.1	11
431	68Ga-PSMA PET/CT imaging in recurrent prostate cancer: Where are we now?. Central European Journal of Urology, 2017, 70, 37-43.	0.2	7
432	NKX3.1 and PSMA are sensitive diagnostic markers for prostatic carcinoma in bone metastasis after decalcification of specimens. American Journal of Clinical and Experimental Urology, 2018, 6, 182-188.	0.4	4
433	[Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review. American Journal of Nuclear Medicine and Molecular Imaging, 2020, 10, 349-374.	1.0	14

#	Article	IF	Citations
434	Combining radionuclide therapy with radiotherapy. , 2021, , .		0
435	Evaluation of 18F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. Translational Oncology, 2022, 15, 101292.	1.7	7
436	68Ga-PSMA11 PET/CT for biochemically recurrent prostate cancer: Influence of dual-time and PMT- vs SiPM-based detectors. Translational Oncology, 2022, 15, 101293.	1.7	4
437	Prognostic Value of Vascular-Expressed PSMA and CD248 in Urothelial Carcinoma of the Bladder. Frontiers in Oncology, 2021, 11, 771036.	1.3	6
438	Utility of different positron emission tomography/computed tomography tracers in the evaluation of incidentally detected dual malignancies: An experience from a tertiary care center. World Journal of Nuclear Medicine, 2021, 20, 382.	0.3	0
439	Changing Threshold-Based Segmentation Has No Relevant Impact on Semi-Quantification in the Context of Structured Reporting for PSMA-PET/CT. Cancers, 2022, 14, 270.	1.7	8
440	PSMA-Targeting Imaging and Theranostic Agentsâ€"Current Status and Future Perspective. International Journal of Molecular Sciences, 2022, 23, 1158.	1.8	37
441	Detection efficacy of PET/CT with 18F-FSU-880 in patients with suspected recurrent prostate cancer: a prospective single-center study. Annals of Nuclear Medicine, 2022, 36, 302.	1.2	1
442	Evaluation of machine learning strategies for imaging confirmed prostate cancer recurrence prediction on electronic health records. Computers in Biology and Medicine, 2022, 143, 105263.	3.9	6
443	Theranostics approach in drug development: is there study efficiency when the prevalence of the molecular target is very high?. Theranostics, 2022, 12, 3079-3083.	4.6	4
444	177Lu-PSMA-617 RLT in mCRPC: A single center experience, the earlier could be the better. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2023, 42, 71-76.	0.1	0
445	PSMA-targeting TGFÎ²-insensitive armored CAR Tâ€‰cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nature Medicine, 2022, 28, 724-734.	15.2	171
446	Prostate-Specific Membrane Antigen Is a Biomarker for Residual Disease following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer. Journal of Urology, 2022, 208, 90-99.	0.2	2
447	Radiomics Analysis on [68Ga]Ga-PSMA-11 PET and MRI-ADC for the Prediction of Prostate Cancer ISUP Grades: Preliminary Results of the BIOPSTAGE Trial. Cancers, 2022, 14, 1888.	1.7	12
448	Imaging and therapeutic targeting of the tumor immune microenvironment with biologics. Advanced Drug Delivery Reviews, 2022, 184, 114239.	6.6	7
449	Disposable electrochemical immunosensor for prostate cancer detection. Sensors and Actuators B: Chemical, 2022, 360, 131667.	4.0	12
450	In silico study on radiobiological efficacy of Ac-225 and Lu-177 for PSMA-guided radiotherapy. , 2021, 2021, 4497-4500.		1
451	Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer. Cancers, 2022, 14, 51.	1.7	12

#	Article	IF	Citations
455	An Explorative Study of the Incidental High Renal Excretion of [18F]PSMA-1007 for Prostate Cancer PET/CT Imaging. Cancers, 2022, 14, 2076.	1.7	1
456	Preclinical Investigations to Explore the Difference between the Diastereomers [¹⁷⁷Lu]Lu-SibuDAB and [¹⁷⁷Lu]Lu-RibuDAB toward Prostate Cancer Therapy. Molecular Pharmaceutics, 2022, 19, 2105-2114.	2.3	7
457	Diagnosis and treatment of metastatic prostate cancer. , 2022, , 23-47.		0
458	Use of Glycoproteinsâ€"Prostate-Specific Membrane Antigen and Galectin-3 as Primary Tumor Markers and Therapeutic Targets in the Management of Metastatic Prostate Cancer. Cancers, 2022, 14, 2704.	1.7	7
461	Novel Role of Prostate-Specific Membrane Antigen in Suppressing Prostate Cancer Invasiveness. Cancer Research, 2005, 65, 727-731.	0.4	83
462	Biological impediments to monoclonal antibodyâ€"based cancer immunotherapy. Molecular Cancer Therapeutics, 2004, 3, 1493-1501.	1.9	100
463	Production and Quality Control of [177Lu]Lu-PSMA-I&T: Development of an Investigational Medicinal Product Dossier for Clinical Trials. Molecules, 2022, 27, 4143.	1.7	7
464	Toward Bifunctional Chelators for Thallium-201 for Use in Nuclear Medicine. Bioconjugate Chemistry, 2022, 33, 1422-1436.	1.8	2
465	Anti-tumor activity of a T-helper 1 multiantigen vaccine in a murine model of prostate cancer. Scientific Reports, 2022, 12, .	1.6	1
466	Prostate specific membrane antigen positron emission tomography in primary prostate cancer diagnosis: First-line imaging is afoot. Cancer Letters, 2022, 548, 215883.	3.2	2
467	The 18F-PSMA-1007 PET/CT performance on metastasis status and therapy assessment in oligo-metastasis prostate cancer. Frontiers in Oncology, 0, 12, .	1.3	1
468	Site-Specific Intact N-Linked Glycopeptide Characterization of Prostate-Specific Membrane Antigen from Metastatic Prostate Cancer Cells. ACS Omega, 2022, 7, 29714-29727.	1.6	2
469	Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	2
470	Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer. Frontiers in Oncology, 0, 12, .	1.3	8
471	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2022, , 1-55.		0
472	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2022, , 1023-1075.		0
474	Prostate-Specific Membrane Antigen-Based PET Brings New Insights into the Management of Prostate Cancer. PET Clinics, 2022, , .	1.5	0
475	Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer. Pharmaceutics, 2022, 14, 2166.	2.0	18

#	Article	IF	Citations
477	Evolving imaging methods of prostate cancer and the emergence of magnetic resonance imaging guided ablation techniques. Frontiers in Oncology, 0, 12, .	1.3	2
478	Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. European Urology, 2023, 83, 521-533.	0.9	10
479	Pharmacological Optimization of PSMA-Based Radioligand Therapy. Biomedicines, 2022, 10, 3020.	1.4	11
480	Building predictive disease models using extracellular vesicle microscale flow cytometry and machine learning. Molecular Oncology, 2023, 17, 407-421.	2.1	4
481	Head-to-head comparison of [68Ga]Ga-P16-093 and 2-[18F]FDG PET/CT in patients with clear cell renal cell carcinoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 1499-1509.	3.3	7
482	Prostate-Specific Membrane Antigen Expression on Positron Emission Tomography/Computed Tomography in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study. Journal of Nuclear Medicine, 0, , jnumed.122.264964.	2.8	4
483	Variability of radiotherapy volume delineation: PSMA PET/MRI and MRI based clinical target volume and lymph node target volume for high-risk prostate cancer. Cancer Imaging, 2023, 23, .	1.2	2
484	In vitro and in vivo comparative study of 68Ga-labeled DOTA-, NOTA-, and HBEDCC-chelated radiotracers targeting prostate-specific membrane antigen. Journal of Radioanalytical and Nuclear Chemistry, 2023, 332, 617-628.	0.7	3
485	Detection Efficacy of 68Ga-PSMA-11 PET/CT in Biochemical Recurrence of Prostate Cancer with Very Low PSA Levels: A 7-Year, Two-Center â€œReal-Worldâ€•Experience. Cancers, 2023, 15, 1376.	1.7	9
486	Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer. JCI Insight, 2023, 8, .	2.3	11
487	Role of bromodomain and extraterminal (BET) proteins in prostate cancer. Expert Opinion on Investigational Drugs, 2023, 32, 213-228.	1.9	3
488	PSMA-Specific Ligands in Prostate Cancer Diagnosis and Therapy. European Medical Journal Urology, 0, , 62-69.	0.0	2
489	Radiotheranostics in advanced prostate cancer: Current and future directions. Prostate Cancer and Prostatic Diseases, 2024, 27, 11-21.	2.0	1
490	Negative predictive value of PSMA PET scan for lymph node staging in patients undergoing robotic radical prostatectomy and pelvic lymph node dissection. International Urology and Nephrology, 0, , .	0.6	0
501	Alpha Particleâ€“Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery. Molecular Imaging and Biology, 2023, 25, 991-1019.	1.3	0
507	How to objectively evaluate the impact of image-guided surgery technologies. European Journal of Nuclear Medicine and Molecular Imaging, 0, , .	3.3	0